Cargando…

Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?

Anti-CTLA-4 and anti-PD-1/PD-L1 immune checkpoint inhibitors are therapeutic monoclonal antibodies that do not target cancer cells but are designed to reactivate or promote antitumor immunity. Dosing and scheduling of these biologics were established according to conventional drug development models...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maritaz, Christophe, Broutin, Sophie, Chaput, Nathalie, Marabelle, Aurélien, Paci, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760805/ https://www.ncbi.nlm.nih.gov/pubmed/35033167 http://dx.doi.org/10.1186/s13045-021-01182-3

Ejemplares similares

Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects
por: Delahousse, Julia, et al.
Publicado: (2020)

Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies
por: Tselikas, Lambros, et al.
Publicado: (2020)

Dose Schedule Optimization and the Pharmacokinetic Driver of Neutropenia
por: Patel, Mayankbhai, et al.
Publicado: (2014)

Scheduling of Anaesthesia Operations in Operating Rooms
por: Hsu, Pi-Yu, et al.
Publicado: (2021)

High-dose thiotepa-related neurotoxicity and the role of tramadol in children
por: Maritaz, Christophe, et al.
Publicado: (2018)

Preparing the SC schedule meeting in the NP Conference Room
por: CERN PhotoLab
Publicado: (1975)

Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria
por: Tarning, Joel, et al.
Publicado: (2022)

Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer
por: Broutin, Sophie, et al.
Publicado: (2016)

Bacterial Cellulose as Drug Delivery System for Optimizing Release of Immune Checkpoint Blocking Antibodies
por: Chung, Chih Kit, et al.
Publicado: (2022)

Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers
por: Baldini, Capucine, et al.
Publicado: (2022)

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
por: Duchemann, Boris, et al.
Publicado: (2020)

Using Simulation Optimization to Solve Patient Appointment Scheduling and Examination Room Assignment Problems for Patients Undergoing Ultrasound Examination
por: Chen, Ping-Shun, et al.
Publicado: (2022)

Optimization Models for Scheduling of Jobs
por: Indika, S. H. Sathish, et al.
Publicado: (2006)

Optimization of a Therapeutic Vaccine Candidate by Studying Routes, Immunization Schedules and Antigen Doses in HBsAg-positive Transgenic Mice
por: Trujillo, H, et al.
Publicado: (2014)

Optimal vaccine schedules to maintain measles elimination with a two-dose routine policy
por: McKEE, A., et al.
Publicado: (2017)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
por: Schneider, Benjamin K., et al.
Publicado: (2019)

Optimizing the Microscopy Time Schedule for Chromosomal Dosimetry of High-dose and Partial-body Irradiations
por: Vinnikov, Volodymyr A.
Publicado: (2017)

Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
por: Marhelava, Katsiaryna, et al.
Publicado: (2019)

Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
por: Gravbrot, Nicholas, et al.
Publicado: (2019)

Application of Operational Research Techniques in Operating Room Scheduling Problems: Literature Overview
por: Gür, Şeyda, et al.
Publicado: (2018)

Solving Operating Room Scheduling Problem Using Artificial Bee Colony Algorithm
por: Lin, Yang-Kuei, et al.
Publicado: (2021)

Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules
por: Toh, Zheng Quan, et al.
Publicado: (2019)

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
por: Karaki, Soumaya, et al.
Publicado: (2016)

COVID19 epidemic outbreak: operating rooms scheduling, specialty teams timetabling and emergency patients' assignment using the robust optimization approach
por: Arab Momeni, Mojtaba, et al.
Publicado: (2022)

Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction
por: Kleibeuker, Esther A, et al.
Publicado: (2015)

Systems Pharmacology Model of Gastrointestinal Damage Predicts Species Differences and Optimizes Clinical Dosing Schedules
por: Shankaran, Harish, et al.
Publicado: (2017)

Optimization of Dose Schedules for Chemotherapy of Early Colon Cancer Determined by High-Performance Computer Simulations
por: Cockrell, Chase, et al.
Publicado: (2019)

A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection
por: Dogra, Prashant, et al.
Publicado: (2023)

A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection
por: Dogra, Prashant, et al.
Publicado: (2023)

Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma
por: Choi, Changhoon, et al.
Publicado: (2019)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

An introduction to optimal satellite range scheduling
por: Vázquez Álvarez, Antonio José, et al.
Publicado: (2015)

Immune Checkpoint Inhibitor Therapy Aggravates T Cell–Driven Plaque Inflammation in Atherosclerosis
por: Poels, Kikkie, et al.
Publicado: (2020)

Geometric Distribution-Based Readers Scheduling Optimization Algorithm Using Artificial Immune System
por: Duan, Litian, et al.
Publicado: (2016)

VIII. Immunological Effectiveness of the Two Dose Schedule
por: Miller, David G., et al.
Publicado: (1962)

nab-Paclitaxel dose and schedule in breast cancer
por: Martín, Miguel
Publicado: (2015)

Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing
por: Ngoune, Romeo, et al.
Publicado: (2018)

What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature
por: Jamison, Caroline, et al.
Publicado: (2016)

Intratumoural administration and tumour tissue targeting of cancer immunotherapies
por: Melero, Ignacio, et al.
Publicado: (2021)

Seronegative antibody‐mediated neurology after immune checkpoint inhibitors
por: Wilson, Robert, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c06p74cn1boftbtqpbpnebt5e2